Are there any recommended nucleic acid detection kits that can simultaneously cover multiple respiratory pathogens?

Quotations for multiplex respiratory panel reagents vary significantly by region, and the listed price for the same product can differ across provinces. It is recommended that you have your sales representative calculate the cost per test of reagent plus consumables directly based on your local reimbursement code, rather than relying solely on the catalog price. Regarding lead time, in-stock items with registration certificates typically ship within one week, while those involving aliquoting or custom batches may take 2–4 weeks. Small-package trials can generally be requested from major manufacturers, but you need to specify whether you want an evaluation pack or a verification pack, and some require signing a trial agreement. When applying, be sure to have the manufacturer provide negative controls, weak positive controls, and reproducibility samples at the same time, and perform matching using your own throat swab preservation solution and extraction reagents to avoid incompatibility if the reagent is used with a different extraction system.

When selecting, don't just look at the number of targets. First ask the manufacturer to provide registration certificates, the limit of detection (LoD) stated in the instructions for use, validation data in throat swab matrix, and clinical data on concordance with singleplex qPCR. Focus on the LoD for influenza A/influenza B/respiratory syncytial virus/adenovirus/Mycoplasma pneumoniae individually, and whether weakly positive samples are stable. For 80-100 samples per day, it is recommended to choose a solution that combines fully automated extraction with multiplex amplification to reduce manual labor and contamination. Also ask the manufacturer whether they have performed competitive validation of multiple targets at low viral load. Some reagents are sensitive in singleplex testing but may miss detection when weakly positive samples are mixed. You can ask the application engineer to bring weakly positive quality control materials on site to test a batch, not just strongly positive samples.

Currently, there are two main approaches for multiplex nucleic acid testing of respiratory pathogens: multi-channel fluorescence PCR and melting curve/single-tube multiplex. Multi-channel is limited by the number of fluorescence channels on the instrument, with 5-6 plex being relatively common; melting curve can cover more targets, but places higher demands on amplification instrument analysis and laboratory contamination prevention. It is recommended to contact 3-4 manufacturers with NMPA registration certificates horizontally, such as Sansure, BioGerm, Da An, and Zhuocheng, to obtain their instructions for comparing target combinations, detection time, and sample preservation solution requirements. Focus on confirming whether they are compatible with your existing extraction instrument and amplification instrument—do not add new equipment just for one box of reagents. In addition, ask clearly whether there is an issue of dominant targets suppressing weakly positive targets in mixed infections.